Abstract
Glatiramer acetate (GA) is one of the most widely used disease-modifying drugs for the treatment of relapsingremitting multiple sclerosis; is assumed to have inductor effects on neurotrophic factor expression. One of these neurotrophic factor systems is the brain-derived neurotrophic factor (BDNF)/receptor tyrosine kinase B (TrkB) pathway. Peripheral blood is thought to contain soluble BDNF, and some blood cells express TrkB. We attempted to determine whether GA treatment leads to changes in plasma BDNF levels and TrkB activation. Such a phenomenon are relapsingremitting multiple sclerosis patients is significantly reduced; GA treatment is not influencing peripheral BDNF levels, after one year of sustained therapy, not from the point of view of total free BDNF nor the phosphorylated TrkB.
Keywords: Brain-derived neurotrophic factor, glatiramer acetate, multiple sclerosis, receptor tyrosine kinase B.
CNS & Neurological Disorders - Drug Targets
Title:Effect of Glatiramer Acetate on Peripheral Blood Brain-Derived Neurotrophic Factor and Phosphorylated TrkB Levels in Relapsing- Remitting Multiple Sclerosis
Volume: 13 Issue: 4
Author(s): Vitalie Vacaras, Zsigmond Z. Major, Dafin F. Muresanu, Tibor L. Krausz, Ioan Marginean and Dana A. Buzoianu
Affiliation:
Keywords: Brain-derived neurotrophic factor, glatiramer acetate, multiple sclerosis, receptor tyrosine kinase B.
Abstract: Glatiramer acetate (GA) is one of the most widely used disease-modifying drugs for the treatment of relapsingremitting multiple sclerosis; is assumed to have inductor effects on neurotrophic factor expression. One of these neurotrophic factor systems is the brain-derived neurotrophic factor (BDNF)/receptor tyrosine kinase B (TrkB) pathway. Peripheral blood is thought to contain soluble BDNF, and some blood cells express TrkB. We attempted to determine whether GA treatment leads to changes in plasma BDNF levels and TrkB activation. Such a phenomenon are relapsingremitting multiple sclerosis patients is significantly reduced; GA treatment is not influencing peripheral BDNF levels, after one year of sustained therapy, not from the point of view of total free BDNF nor the phosphorylated TrkB.
Export Options
About this article
Cite this article as:
Vacaras Vitalie, Major Z. Zsigmond, Muresanu F. Dafin, Krausz L. Tibor, Marginean Ioan and Buzoianu A. Dana, Effect of Glatiramer Acetate on Peripheral Blood Brain-Derived Neurotrophic Factor and Phosphorylated TrkB Levels in Relapsing- Remitting Multiple Sclerosis, CNS & Neurological Disorders - Drug Targets 2014; 13 (4) . https://dx.doi.org/10.2174/1871527313666140618110049
DOI https://dx.doi.org/10.2174/1871527313666140618110049 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Microglial Proteases: Strategic Targets for Neuroprotective Agents
Current Neuropharmacology Proteostasis, an Emerging Therapeutic Paradigm for Managing Inflammatory Airway Stress Disease
Current Molecular Medicine Phosphodiesterase Inhibitors as Therapeutics for Traumatic Brain Injury
Current Pharmaceutical Design Search and Rescue: Identification of Cannabinoid Actions Relevant for Neuronal Survival and Protection
Current Neuropharmacology Cannabinoid Receptor Type 2 Activation in Atherosclerosis and Acute Cardiovascular Diseases
Current Medicinal Chemistry Recent Updates in Imperative Natural Compounds for Healthy Brain and Nerve Function: A Systematic Review of Implications for Multiple Sclerosis
Current Drug Targets Astrocyte Signaling and Multiple Sclerosis
Current Signal Transduction Therapy Gene Expression Studies in Multiple Sclerosis
Current Genomics Extracellular Domain Of Myelin Oligodendrocyte Glycoprotein (Mog) Exhibits Solvent-Dependent Conformational Transitions
Protein & Peptide Letters Application of Phage Display Technology to Cancer Research
Current Pharmaceutical Biotechnology Pattern Recognition by CD6: A Scavenger-Like Lymphocyte Receptor
Current Drug Targets Molecular Approach to Targeted Therapy for Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Central Nervous System Agents in Medicinal Chemistry Gender Hormones: Role in the Pathogenesis of Central Nervous System Disease and Demyelination
Current Neurovascular Research Chemokine-Chemokine Receptor Network in Immune Cell Trafficking
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Experimental Models of Relapsing-Remitting Multiple Sclerosis: Current Concepts and Perspective
Current Neurovascular Research Expression and Functions of Innate Pattern Recognition Receptors in T and B Cells
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) From the Oxygen to the Organ Protection: Erythropoietin as Protagonist in Internal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry Are Circulating Monocytes as Microglia Orthologues Appropriate Biomarker Targets for Neuronal Diseases? (Supplementry Table)
Central Nervous System Agents in Medicinal Chemistry Muramyl Dipeptide and its Derivatives: Peptide Adjuvant in Immunological Disorders and Cancer Therapy
Current Bioactive Compounds